LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
LVAC was delisted on the 10th of May, 2023.
47 hedge funds and large institutions have $93.7M invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
21% more funds holding
Funds holding: 39 → 47 (+8)
8% more capital invested
Capital invested by funds: $86.6M → $93.7M (+$7.11M)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$4.99M |
| 2 |
JP Morgan Chase
New York
|
+$3.99M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.99M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$3.15M |
| 5 |
Millennium Management
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$9.94M |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
-$2.25M |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$29.1K |
| 4 |
FTCM
Fir Tree Capital Management
New York
|
-$4.99K |
| 5 |
Walleye Capital
New York
|
-$2K |
LVAC Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q2 2022, worth a combined $93.7M — up 8.2% from $86.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LVAC positions and 2 closed out — a net gain of 8 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Saba Capital Management, adding an estimated $4.99M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $9.94M sold.
- 47 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $93.7M of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q2 2022, up 8.2% quarter-over-quarter.
- 10 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q2 2022 and 2 closed out, a net change of +8 holders.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock buyer in Q2 2022 was Saba Capital Management, an estimated $4.99M added.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q2 2022 was Beryl Capital Management, an estimated $9.94M sold.
Based on aggregated 13F filings for Q2 2022.